HUNTSVILLE – Score Pharma of Huntsville was recently selected as a finalist in the title round pitch competition at ConvergeSouth 2025 and participated as an exhibitor at the event held in Winston-Salem, N.C.
A biopharmaceutical company pioneering next-generation therapeutic antibody platforms, Score Pharma is on the HudsonAlpha Institute for Biotechnology’s Huntsville campus and is in a strategic partnership with Southern Research in Birmingham.
ConvergeSouth, a premier southeast technology and innovation conference, brings together founders, investors and industry executives to highlight high-growth companies shaping the future of their sectors.
“Being named a finalist at ConvergeSouth underscores both the scientific and commercial potential of our platform,” said Bruce Jones, Ph.D., founder and CEO of Score Pharma. “We are committed to advancing therapies that deliver meaningful patient impact while creating long-term value for our investors.
“This recognition at ConvergeSouth 2025 represents a milestone in our growth trajectory and validates our position as an emerging leader in the biopharmaceutical sector.”
As an exhibitor, the Huntsville-based company presented its differentiated approach to antibody drug development with initial targets focused on oncology, drawing significant engagement from investors and potential strategic partners.
Don’t miss out! Subscribe to our email newsletter to have all our smart stories delivered to your inbox.
